Sunday 18 October 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMR
Alamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024. Insiders bought in the last twelve months.
25.28
2.14
−7.80%
Follow ALMR
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 222 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.33 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 25 | 74 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | 34.23 | 56.20 | |||||
| EBT | — | — | — | — | — | — | — | — | (47) | (29) | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | (187.18) | (39.29) | |||||
| Net income | — | — | — | — | — | — | — | — | (47) | (30) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 1 | 4 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 2.39 | 6.43 | ||||
| Earnings | — | — | — | — | — | — | — | — | (4.47) | (2.58) | |||||
| Cash flow | — | — | — | — | — | — | — | — | (5.25) | (4.64) | |||||
| Capex | — | — | — | — | — | — | — | — | (0.28) | (0.47) | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (5.53) | (5.11) | |||||
| Book value | — | — | — | — | — | — | — | — | 9.65 | 6.59 | |||||
| Shares, m | — | — | — | — | — | — | — | — | 11 | 12 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | (2.64) | (2.64) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (55) | (54) | ||||
| Capex | — | — | — | — | — | — | — | — | (3) | (5) | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (58) | (59) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 90 | 71 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | 10 | |||||
| Net debt | — | — | — | — | — | — | — | — | (80) | (20) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 102 | 76 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (20.60) | ||||
| ROIC | — | — | — | — | — | — | — | — | (141.04) | (35.06) | |||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 20.40 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Alamar Biosciences, Inc. vs peers (Q) = latest quarter vs a year earlier
Alamar Biosciences, Inc. (ALMR) key facts
- Concern: Alamar Biosciences, Inc. reported a net loss of $29.8 million, or a loss of $2.58 per share, for fiscal 2025.
- Strength: Alamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024.
- As of October 16, 2026, ALMR traded at $25.28, a market capitalization of $1.9 billion.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 17.5× sales.
- Return on equity was 20.4% and debt-to-equity 0.03.
Alamar Biosciences, Inc. (ALMR) Latest News
No news at this impact. Lower the threshold for more.